Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CEO Sells 22,500 Shares of Stock

Key Points

• CEO Eric Dube sold 22,500 shares on May 6 at an average price of $43.95 for $988,875, reducing his stake by 4.94% to 432,886 shares; the trade was made under a pre‑arranged Rule 10b5‑1 plan and disclosed on an SEC Form 4.
• Travere beat Q1 EPS estimates with $0.05 (vs. -$0.24 expected) and posted 55.6% year‑over‑year revenue growth to $127.2M, but revenue missed analyst forecasts and the company still shows negative net margin and ROE.
• Several analysts have raised price targets and ratings recently, leaving the consensus at a Moderate Buy with a $47.83 target, while the stock trades around $44.70 near its 52‑week high.

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CEO Eric Dube sold 22,500 shares of the firm's stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $43.95, for a total transaction of $988,875.00. Following the completion of the transaction, the chief executive officer owned 432,886 shares of the company's stock, valued at $19,025,339.70. This trade represents a 4.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Price Performance

Travere Therapeutics stock traded down $0.10 during midday trading on Wednesday, reaching $44.70. 2,390,035 shares of the stock were exchanged, compared to its average volume of 2,890,153. The company's fifty day moving average is $32.59 and its 200-day moving average is $32.83. The company has a debt-to-equity ratio of 3.16, a quick ratio of 2.70 and a current ratio of 3.13. The firm has a market cap of $4.16 billion, a PE ratio of -194.33 and a beta of 1.13. Travere Therapeutics, Inc. has a 52 week low of $13.88 and a 52 week high of $48.61.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its earnings results on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.29. The business had revenue of $127.20 million for the quarter, compared to analyst estimates of $136.23 million. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. Travere Therapeutics's revenue was up 55.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.47) EPS. On average, sell-side analysts forecast that Travere Therapeutics, Inc. will post -0.16 EPS for the current year.

Wall Street Analyst Weigh In

TVTX has been the topic of a number of analyst reports. Citigroup upped their target price on shares of Travere Therapeutics from $53.00 to $59.00 and gave the stock a "buy" rating in a report on Tuesday. HC Wainwright boosted their price objective on Travere Therapeutics from $47.00 to $57.00 and gave the stock a "buy" rating in a report on Tuesday. Guggenheim boosted their price objective on Travere Therapeutics from $54.00 to $56.00 and gave the stock a "buy" rating in a report on Friday, April 24th. Wells Fargo & Company boosted their price objective on Travere Therapeutics from $40.00 to $50.00 and gave the stock an "overweight" rating in a report on Wednesday. Finally, Canaccord Genuity Group boosted their price objective on Travere Therapeutics from $47.00 to $56.00 and gave the stock a "buy" rating in a report on Tuesday, April 14th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Travere Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $47.83.

Trending Headlines about Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target from $45 to $60 and kept a "buy" rating, implying meaningful upside vs. current levels — a bullish signal from a major sell‑side shop. TD Cowen price target raise
• Positive Sentiment: Wells Fargo upgraded its target to $50 and assigned an "overweight" rating, another near‑term positive catalyst supporting higher valuation expectations. Wells Fargo price target raise
• Neutral Sentiment: HC Wainwright reiterated a "Buy" and $57 target but trimmed FY2027–FY2030 EPS forecasts slightly (e.g., FY2027 cut from $0.71 to $0.60; FY2030 to $4.59 from $4.61). The firm still models substantial multi‑year growth, so this is more of a modest forecast tweak than a change in conviction. HC Wainwright note
• Neutral Sentiment: Earnings call transcript for Q1 2026 is available — recall Travere reported a year‑over‑year revenue gain and an EPS beat in the quarter, which helped underpin recent analyst upgrades. Review the transcript for management commentary on sparsentan commercialization and margin trajectory. Q1 2026 earnings transcript
• Negative Sentiment: Director Roy Baynes sold 9,750 shares (about $431k at the sale price) under a pre‑arranged Rule 10b5‑1 plan. Insider sales can be perceived negatively by the market despite the trading plan disclosure; monitor for any further insider activity. Insider sale filing

Institutional Trading of Travere Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. State of Wyoming purchased a new stake in Travere Therapeutics in the fourth quarter worth approximately $37,000. Torren Management LLC purchased a new stake in Travere Therapeutics in the fourth quarter worth approximately $38,000. Comerica Bank boosted its stake in Travere Therapeutics by 77.5% in the fourth quarter. Comerica Bank now owns 1,127 shares of the company's stock worth $43,000 after buying an additional 492 shares in the last quarter. Fifth Third Bancorp purchased a new stake in Travere Therapeutics in the first quarter worth approximately $35,000. Finally, Smartleaf Asset Management LLC boosted its stake in Travere Therapeutics by 69.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company's stock worth $45,000 after buying an additional 487 shares in the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.